The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.

April 24 (Reuters) - France's Sanofi (SASY.PA), opens new tab reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug ...

Analysts fell to the sidelines weighing in on Biogen (BIIB – Research Report) and Sanofi (SNY – Research Report) with neutral ratings, ...

$2,540,000 of SANOFI US SERVICES INC lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Drug Pricing - General Issues ...

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma refocuses its relationship with Innate Pharma from oncology to ...

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

The so-called 'Most Favored Nations' rule would set drug pricing for Medicare in line with the prices paid by other nations, ...

Sanofi backed its full-year guidance after higher first-quarter sales and profit that beat analysts' expectations. The French pharmaceutical company said Thursday that business operating profit ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

And Sanofi solicits new ideas from employees. It even holds an annual Planet Care Challenge offering rewards to workers with ...